Company Overview and News

 
Mixed fortunes for billionaire owners as stocks struggle to hold gains

2018-03-09 thestar.com.my
KUALA LUMPUR: Billionaire bankers and palm oil planters continue to see their wealth grow year-to-date, as the share price of their flagship companies outperformed the broader stock market rise, fuelled by strong earnings outlook.
Upvote Downvote

 
Bursa ends with a bang on buying sentiment

2018-02-27 themalaymailonline
KUALA LUMPUR, Feb 27 — Bursa Malaysia reversed yesterday’s losses and finished at more than three-week high today, spurred by persistent buying momentum in selected large-capitalised stocks amid corporate earnings season.
Upvote Downvote

 
Diary Malaysia 2018 corporate earnings

2018-02-19 thestar.com.my
KUALA LUMPUR: Following is a list of release dates for the quarterly earnings of some top Malaysia-listed companies.
Upvote Downvote

 
FBM KLCI to hit 1,900 points despite recent drops

2018-02-16 thestar.com.my
The recommendation comes a week after the FBM KLCI saw its biggest single-day drop since December 2014 of 2.19% to a 23-trading day low of 1,812 points.(Filepic)
Upvote Downvote

 
Bursa Malaysia well supported by fundamentals

2018-02-13 thestar.com.my
KUALA LUMPUR: Maybank Investment Bank said Bursa Malaysia is well supported by sound domestic fundamentals despite the recent sell down stoked by the Dow Jones's correction. The investment bank said in a 1H 2018 Market Outlook session that it expects fiscal stimulus pre-GE14 and Bank Negara's overnight policy rate (OPR) hike to be the two main thematics driving investment.
Upvote Downvote

 
Foreign funds sell RM1.75bil of Malaysian shares

2018-02-12 thestar.com.my
KUALA LUMPUR: There was an exodus of foreign funds from stocks listed on Bursa after six straight weeks of buying, according to MIDF Research.  
Upvote Downvote

1
Malaysia’s top 40 richest people

2018-02-03 thestar.com.my
LAST year was dotted by the return of higher commodity prices and better economic growth. The world’s economies on average are back in business as growth rates and trade have started to improve once again after some period of uncertainty caused by a cooling China economy and also the slump in global crude oil prices.
Upvote Downvote

 
Malaysian banks gain on rate hike news

2018-01-25 themalaymailonline
Share prices of major local financial institutions rise after Bank Negara Malaysia announces a 25 basis point increase to its overnight policy rate. — Reuters file picKUALA LUMPUR, Jan 25 — Stocks of major local financial institutions rose after Bank Negara Malaysia announced a 25 basis point increase to its overnight policy rate, with some hitting historic highs.
Upvote Downvote

 
Finance stocks lift KL shares to end 10 pts higher

2017-12-12 themalaymailonline
KUALA LUMPUR, Dec 12 — Bursa Malaysia, which started trading on an easier note, finished higher today, driven by gains in most blue chip finance stocks led by CIMB Group.
Upvote Downvote

 
Bursa up slightly at mid-day

2017-12-12 themalaymailonline
KUALA LUMPUR, Dec 12 — Bursa Malaysia rebounded at mid-day from its lower opening earlier as buyers started to nibble on stocks in a market interspersed with mild profit-taking.
Upvote Downvote

 
KLCI gains ground on positive Chinese trade data

2017-12-08 thestar.com.my
KUALA LUMPUR: Asian markets were given a boost on Friday as Chinese trade data was showed to accelerate in October. The local benchmark index was also on the rise, gaining 4.24 points to 1,723.29 points. Turnover was 961.42 million shares with a value of RM1.05bil. Market breadth remained negative, with 337 decliners versus 230 gainers and 473 counters unchanged. Banking stocks came into play on the local market, with Hong Leong Bank rising 10 sen higher to RM16.
Upvote Downvote

 
KL shares end morning session lower

2017-12-06 themalaymailonline
KUALA LUMPUR, Dec 6 — Bursa Malaysia ended the morning session lower today on weaker buying sentiment in the overall market, led by financial stocks.
Upvote Downvote

 
Blue chips give up early gains; oil prices slip

2017-11-15 thestar.com.my
KUALA LUMPUR: The local bourse moved into negative territory less than an hour into the morning session as blue chips gave up early gains and Maybank weighed. Regionally, equity markets were in the red as Wall Street came under pressure from declining oil prices.  US energy stocks including General Electric brought US indexes lower as oil prices slipped from 28-month highs achieved last week. At midday, the FBM KLCI was 1.
Upvote Downvote

 
Bursa ends lower on profit-taking

2017-11-10 themalaymailonline
KUALA LUMPUR, Nov 10 — Bursa Malaysia finished the week lower on profit-taking in selected heavyweights and trade and services counters, dealers said.
Upvote Downvote

 
KL shares higher in early trade

2017-11-06 themalaymailonline
Market breadth was positive with gainers outpacing decliners 227 to 124 while 224 counters were unchanged, 1,239 untraded and 29 others were suspended. — Bernama picKUALA LUMPUR, Nov 6 — Bursa Malaysia opened higher on Monday prompted by buying interest for selected heavyweights.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...